The acquisition would give Kerry additional technology to create lactose-free and reduced-sugar dairy products.
Kerry Group plc (Tralee, Ireland) announced plans to acquire part of the global lactase enzyme business belonging to Chr. Hansen Holding A/S and Novozymes A/S.
“The acquisition is subject to European Commission approval of Kerry as a buyer and forms part of the Novozymes and Chr. Hansen merger-approval process,” Kerry’s press release notes.
The acquisition would boost Kerry’s enzyme technology to create lactose-free and reduced-sugar dairy products, the firm says. Kerry had already acquired enzyme manufacturers c-LEcta and Enmex. This latest acquisition would further bolster the company’s biotechnology capabilities.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.